Global Non-small Cell Lung Cancer Therapeutics Market Size To Exceed USD 78.65 Billion By 2035 | CAGR of 12.59%
Category: HealthcareGlobal Non-small Cell Lung Cancer Therapeutics Market Size To Exceed USD 78.65 Billion By 2035
According to a research report published by Spherical Insights & Consulting, the Global Non-small Cell Lung Cancer Therapeutics Market Size is expected to grow from USD 21.35 Billion in 2024 to USD 78.65 Billion by 2035, at a CAGR of 12.59% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 253 pages with 127 Market data tables and figures & charts from the report on the "Global Non-small Cell Lung Cancer Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type (Squamous Cell Carcinoma, Large Cell Carcinoma, Adenocarcinoma, and Others), By Treatment (Chemotherapy, Targeted Therapy, Immunotherapy, and Others), By Distribution Channel (Hospital Pharmacy, Targeted Therapy, Immunotherapy, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/non-small-cell-lung-cancer-therapeutics-market
The non-small cell lung cancer therapeutics market refers to the industry of pharmaceuticals and the treatment landscape for non-small cell lung cancer, which is the most common type of lung cancer. The non-small cell lung cancer therapeutics market is driven by an increasing prevalence rate of lung disorders, along with the rising consumption of tobacco products, deterioration of air quality, and unhealthy lifestyles. The rising research & development activities and novel targeted & immunotherapy approaches are escalating the market growth opportunities. The development of personalized medicine, emphasizing novel targeted therapies for the treatment of cancers, such as non-small lung cancer, is driving the market. However, the incidence of drug resistance and competition from generics & biosimilars are restraining the non-small cell lung cancer therapeutics market.
The adenocarcinoma segment dominated the market with a significant share in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type, the non-small cell lung cancer therapeutics market is divided into squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Among these, the adenocarcinoma segment dominated the market with a significant share in 2024 and is projected to grow at a substantial CAGR during the forecast period. The increasing tobacco consumption and other products of smoking are responsible for propelling the market demand in the adenocarcinoma segment.
The targeted therapy segment accounted for a major market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the treatment, the non-small cell lung cancer therapeutics market is divided into chemotherapy, targeted therapy, immunotherapy, and others. Among these, the targeted therapy segment accounted for a major market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Tyrosine kinase inhibitors such as EGFR and ALK inhibitors are the drugs used in targeted therapy that specifically target genetic mutations or pathways that drive cancer growth and spread.
The hospital pharmacy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.
Based on the distribution channel, the non-small cell lung cancer therapeutics market is divided into hospital pharmacy, targeted therapy, immunotherapy, and others. Among these, the hospital pharmacy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. An increasing number of hospitalized patients suffering from NSCLC, with the growing availability of medicines and treatments, are propelling the non-small cell lung cancer therapeutics market.
North America is expected to hold the majority share of the global non-small cell lung cancer therapeutics market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global non-small cell lung cancer therapeutics market during the forecast period. The increasing adoption of advanced immunotherapies and other critical therapies, including chemotherapy & targeted therapy in the developed countries of the region, is driving the regional market. Further, the presence of well-developed healthcare facilities with an increasing awareness about cancer treatment is propelling the market.
Asia Pacific is anticipated to grow at the fastest pace in the global non-small cell lung cancer therapeutics market during the forecast period. The rising government investment in oncology care, with an increasing prevalence of lung cancer, is driving the market. Further, environmental pollution and smoking are contributing factors to the non-small cell lung cancer therapeutics market growth.
Europe is anticipated to hold a significant share of the non-small cell lung cancer therapeutics market during the projected timeframe. The availability of highly efficient drugs and emphasis on targeted therapies for non-small lung cancer are driving the market. In addition, the region’s major medical institutes and the growing number of consumers addicted to smoking are propelling regional market growth.
Major vendors in the global non-small cell lung cancer therapeutics market are F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GSK plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In August 2024, A supplemental new drug application (sNDA) for a first-in-class PD-1/VEGF bispecific immunotherapy agent, ivonescimab (AK112), has been granted priority review by the National Center for Drug Evaluation for the State Drug Administration of the People’s Republic of China for the frontline treatment of patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the non-small cell lung cancer therapeutics market based on the below-mentioned segments:
Global Non-small Cell Lung Cancer Therapeutics Market, By Type
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Adenocarcinoma
- Others
Global Non-small Cell Lung Cancer Therapeutics Market, By Treatment
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
Global Non-small Cell Lung Cancer Therapeutics Market, By Distribution Channel
- Hospital Pharmacy
- Targeted Therapy
- Immunotherapy
- Others
Global Non-small Cell Lung Cancer Therapeutics Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?